Success Metrics

Clinical Success Rate
100.0%

Based on 3 completed trials

Completion Rate
100%(3/3)
Active Trials
0(0%)
Results Posted
0%(0 trials)

Phase Distribution

Ph phase_4
1
25%
Ph phase_2
1
25%
Ph not_applicable
1
25%

Phase Distribution

0

Early Stage

1

Mid Stage

1

Late Stage

Phase Distribution3 total trials
Phase 2Efficacy & side effects
1(33.3%)
Phase 4Post-market surveillance
1(33.3%)
N/ANon-phased studies
1(33.3%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

75.0%

3 of 4 finished

Non-Completion Rate

25.0%

1 ended early

Currently Active

0

trials recruiting

Total Trials

4

all time

Status Distribution
Completed(3)
Terminated(1)

Detailed Status

Completed3
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
4
Active
0
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Phase 21 (33.3%)
Phase 41 (33.3%)
N/A1 (33.3%)

Trials by Status

completed375%
withdrawn125%

Recent Activity

0 active trials
Showing 4 of 4
completedphase_2

Octreotide Treatment to Improve Nutritional Recovery After Surgery for Patients with Esophageal or Gastric Cancer

NCT04871204
withdrawnnot_applicable

Macro and Microcirculatory Effects of the Combination of Norepinephrine and Octreotide for the Treatment of Cirrhotic Patients With Hemorrhagic Shock

NCT03891849
completedphase_4

The Effect of Octreotide on Wound Drainage After Mastectomy

NCT05682209
completed

Efficacy and Safety Evaluation of Octreotide in the Treatment of Congenital Hyperinsulinemia

NCT05171751

Clinical Trials (4)

Showing 4 of 4 trials
NCT04871204Phase 2

Octreotide Treatment to Improve Nutritional Recovery After Surgery for Patients with Esophageal or Gastric Cancer

Completed
NCT03891849Not Applicable

Macro and Microcirculatory Effects of the Combination of Norepinephrine and Octreotide for the Treatment of Cirrhotic Patients With Hemorrhagic Shock

Withdrawn
NCT05682209Phase 4

The Effect of Octreotide on Wound Drainage After Mastectomy

Completed
NCT05171751

Efficacy and Safety Evaluation of Octreotide in the Treatment of Congenital Hyperinsulinemia

Completed

All 4 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
4